ArticleNature communications2025
A robust platform streamlining aromatic noncanonical amino acid biosynthesis and genetic code expansion in Escherichia coli.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Phage-assisted continuous evolution of enzymes for noncanonical tyrosine biosynthesis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Genetically Encoded Lysine-Selective Photocyclization Enables Phage Display Selection of Cyclic Peptide Binders.Angewandte Chemie (International ed. in English) · 2026Article
- Engineering rhizobacterial communities for soil and plant health.Microbiology (Reading, England) · 2026Review
- Phage-assisted continuous evolution of enzymes for noncanonical tyrosine biosynthesis.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Genetic code expansion (GCE) has significantly enhanced the diversity of proteins in the biological world, leading to a wide range of applications. Despite the advances in GCE, the cost of noncanonical amino acids (ncAAs) remains one of the major obstacles for large-scale production. In situ biosynthesis of ncAAs from commercial precursors offers a promising solution to this challenge, yet only a few biosynthetic pathways have been reported. Here, we present a platform that couples the biosynthesis of aromatic ncAAs with genetic code expansion in E. coli, enabling the production of proteins and peptides containing ncAAs. Forty ncAAs are synthesized from aryl aldehydes by the biosynthetic pathway, while nineteen ncAAs are incorporated into superfolder GFP using three orthogonal translation systems. The platform's versatility is demonstrated by the production of macrocyclic peptides and antibody fragments. We envision that the platform will facilitate the production of peptides, enzymes, and antibody fragments containing ncAAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.